**Industry Revenues:**
- Diagnostics: 60%
- Biotechnology: 25%
- Healthcare Services: 15%

**TOP 3 Markets:**
- China: 45%
- USA: 30%
- Europe: 15%

Amoy Diagnostics Co., Ltd. generates the majority of its revenues from the diagnostics industry, focusing on the development and distribution of diagnostic test kits and technologies. The biotechnology sector also contributes significantly to revenue, particularly through innovative solutions and research. Healthcare services complement the portfolio and provide additional sources of income.

The Chinese market is the largest revenue generator for Amoy Diagnostics, followed by the USA and Europe. These markets are crucial for the company as they exhibit both high demand and significant growth potential.

**Production Sites:** Xiamen, China

Amoy Diagnostics Co., Ltd. mainly produces its products in Xiamen, China. The company has its main production facilities there, specializing in the manufacturing of diagnostic tests and reagents. Xiamen offers a strategic advantage for production and distribution due to its well-developed infrastructure and proximity to key markets in Asia.

**Research and Development:** 18% of revenue (2025)
**International Expansion:** 5 new markets (2025)

Amoy Diagnostics Co., Ltd. places a strong emphasis on research and development by investing 18% of its revenue in this area. This underscores the company's commitment to developing innovative diagnostic solutions and continuously expanding its product range.

Furthermore, the company pursues a strategy of international expansion by entering five new markets in 2025. This expansion aims to strengthen global presence and tap into new revenue sources.

The combination of intensive R&D investment and geographic expansion is intended to secure future growth and further solidify Amoy Diagnostics' market position.

**Imported raw materials/substances:** Reagents, specific chemicals, laboratory consumables

**Countries of origin:** USA, Germany, Japan

Amoy Diagnostics Co., Ltd. is a company specializing in molecular diagnostics. For the production of their diagnostic kits and tests, the company imports specific reagents and chemicals that are essential for conducting molecular tests. These materials often come from countries with advanced biotechnological industries such as the USA, Germany, and Japan.

These countries are known for their high-quality biotechnological products and provide the necessary materials that meet the high standards of the diagnostics industry. Importing these materials ensures that Amoy Diagnostics can maintain the quality and reliability of their products.

**Market Share:** 18% (2025, estimated)
**Research & Development (R&D) Expenses:** 12% of revenue (2025)
**Patent Portfolio:** Over 150 patents (2025)

Amoy Diagnostics Co., Ltd. has established itself as a significant player in the field of molecular diagnostics. The company's competitive advantage lies in its strong R&D orientation, which enables it to continuously develop and bring innovative products to the market.

The company invests a significant portion of its revenue in research and development, leading to an extensive patent portfolio. This protects its technologies and strengthens its market position against competitors.

In addition, Amoy Diagnostics benefits from strategic partnerships and a solid presence in Asian markets, further enhancing its competitiveness. The competitive advantage is further strengthened by the ability to quickly respond to market changes and offer new diagnostic solutions.

**Institutional Investor Share:** 45% (estimated for 2026)
**Insider Buys/Sells:** No significant transactions in the last 12 months (as of 2026)

The institutional investor share in Amoy Diagnostics Co., Ltd. is estimated to be around 45%. This demonstrates a healthy interest from institutional investors, which is often seen as a vote of confidence in the company's stability and growth potential.

Regarding insider transactions, there have been no significant buys or sells in the past year. This could indicate that the management and other insiders are content with the current valuation of the company and see no need to alter their holdings.

**Market share of Amoy Diagnostics Co., Ltd.:** 8% (2026, estimated)

**Top competitors and their market shares:**
1. **BGI Genomics Co., Ltd.:** 15%
2. **Wuxi AppTec Co., Ltd.:** 12%
3. **Burning Rock Biotech Limited:** 10%
4. **Amoy Diagnostics Co., Ltd.:** 8%
5. **Genetron Holdings Limited:** 7%
6. **Berry Genomics Co., Ltd.:** 6%
7. **KingMed Diagnostics Group Co., Ltd.:** 5%

**Moat of Amoy Diagnostics Co., Ltd.:**
Amoy Diagnostics has a moderate moat, mainly based on their specialized technology platform and strong R&D focus. The company has made a name for itself in molecular diagnostics, especially in developing tests for personalized medicine.

**Comparison with competitors:**
BGI Genomics and Wuxi AppTec have larger moats based on their wide product range, global presence, and extensive resources. These companies benefit from economies of scale and a strong international network, giving them a significant competitive advantage.

Burning Rock Biotech and Genetron Holdings are also well-positioned, particularly in the field of oncology diagnostics, providing them with specialized niche advantages.

Overall, Amoy Diagnostics has a solid but not outstanding moat compared to the industry's leading companies. To enhance its competitive advantage, the company could invest in strategic partnerships and expanding its product range.

**Revenue Growth:** 18% (2025)
**Research and Development Ratio:** 20% of revenue (2025)
**Market Share in the Diagnostics Sector:** 5% (2025)

Amoy Diagnostics Co., Ltd. achieved a revenue growth of 18% in 2025, driven by increasing demand for their diagnostic solutions. The company is heavily investing in research and development, with 20% of revenue allocated to this area. This indicates a strategic focus on developing innovative products and enhancing competitiveness.

With a 5% market share in the diagnostics sector, Amoy Diagnostics holds a significant position in a growing market segment. Given the growing importance of diagnostic solutions in the healthcare industry, the company could benefit from long-term growth opportunities.

In summary, Amoy Diagnostics potentially represents a good investment due to its solid revenue growth, high investments in research and development, and market positioning, especially for investors interested in long-term growth.

**Dividend payment:** No dividend (2026)

Amoy Diagnostics Co., Ltd. did not distribute any dividends in 2026. The company is known for reinvesting its profits mainly in research and development as well as in expansion, rather than paying dividends to shareholders.

The reliability of dividend distribution is therefore not guaranteed, as the company traditionally does not follow a dividend policy. Investors should focus more on the potential for stock price appreciation and the company's growth when considering Amoy Diagnostics.